within Pharmacolibrary.Drugs.ATC.R;

model R01AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 4.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0027,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0038333333333333336,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ephedrine is a sympathomimetic amine and alkaloid, traditionally used as a decongestant, bronchodilator, and stimulant in the treatment of asthma, bronchitis, nasal congestion, and hypotension due to anesthesia. Its use is now limited because of side effects and availability of safer alternatives. It is approved in some countries for specific indications, but its misuse as a stimulant and for weight loss has led to restrictions in many jurisdictions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after single oral administration.</p><h4>References</h4><ol><li><p>Kanfer, I, et al., &amp; Vuma, V (1993). Pharmacokinetics of oral decongestants. <i>Pharmacotherapy</i> 13(6 Pt 2) 116S–146S. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7507589/\">https://pubmed.ncbi.nlm.nih.gov/7507589</a></p></li><li><p>Wellington, K, &amp; Jarvis, B (2001). Cetirizine/pseudoephedrine. <i>Drugs</i> 61(15) 2231–2242. DOI:<a href=\"https://doi.org/10.2165/00003495-200161150-00009\">10.2165/00003495-200161150-00009</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11772135/\">https://pubmed.ncbi.nlm.nih.gov/11772135</a></p></li><li><p>Pickup, ME, et al., &amp; Paterson, JW (1976). The pharmacokinetics of ephedrine after oral dosage in asthmatics receiving acute and chronic treatment. <i>British journal of clinical pharmacology</i> 3(1) 123–134. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1976.tb00579.x\">10.1111/j.1365-2125.1976.tb00579.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/973934/\">https://pubmed.ncbi.nlm.nih.gov/973934</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AA03;
